Losartan Potassium Tablet, Film Coated
Product Images NDC 43063-954

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 43063-954). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063954 Label (43063954)

Label for Losartan Potassium USP 100 mg film-coated tablets, 30 count, from PD-Rx Pharmaceuticals, Inc. The label includes the NDC number 43063-954-30 and manufacturer details with a green warning box about keeping out of reach of children. It also shows reorder number, lot number D19E38, and expiration date 04/2021. The label has dosage instructions and safety warnings in English and partially in Spanish.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over time between Losartan Potassium and Atenolol groups during a study lasting up to 66 months. The graph includes an annotation indicating an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure2 (Losartan Fig2)

A line chart comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium. The chart includes an annotation indicating an adjusted risk reduction of 25% with a p-value of 0.001, showing Losartan Potassium with a consistently lower risk than Atenolol throughout the study period.*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios between Losartan Potassium and Atenolol. The graph shows event rates (%) for primary composite outcomes and stroke (fatal/non-fatal) across subgroups including age, gender, race, ISH, diabetes, and history of cardiovascular disease. The hazard ratios with 95% confidence intervals indicate comparative risk favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The graph shows event progression on the y-axis and time in months on the x-axis, with Losartan Potassium represented by a solid line and placebo by a dashed line, indicating a reported risk reduction of 16.1% with statistical significance (p=0.022).*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium, depicting its molecular arrangement including aromatic rings and functional groups, corresponding to the active ingredient in the pharmaceutical product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.